Abstract: The invention provides a reaction system for preparing butyraldehyde by propylene carbonylation, comprising: a reactor; a side wall of the reactor is sequentially provided with a catalyst inlet, a propylene inlet and a synthesis gas inlet from top to bottom; the bottom of the reactor is provided with a solvent inlet; two micro-interface generators are arranged inside of the reactor from top to bottom, and the micro-interface generator located at a top end is connected to the propylene inlet to break the propylene gas into micron-scale micro-bubbles; the micro-interface generator located at a bottom is connected to the synthesis gas inlet for breaking the synthesis gas into micron-scale micro-bubbles; the outlets of the two micro-interface generators are opposite, and the outlets are connected with a gas distributor for evenly distributing raw materials.

Abstract: The present system reduces the cost of carbon capture by reducing the over-temperature needed to strip CO2 from a liquid or fluid solution. The system includes structures that enhance the rate of CO2 bubble nucleation.

Abstract: An electrochemical device converts carbon dioxide to a formic acid reaction product. The device includes an anode and a cathode, each comprising a quantity of catalyst. The anode and cathode each have reactant introduced thereto. A cation exchange polymer electrolyte membrane and an anion exchange polymer electrolyte membrane, are interposed between the anode and the cathode, forming a central flow compartment where a carbon dioxide reduction product, such as formic acid, can be recovered. At least a portion of the cathode catalyst is directly exposed to gaseous carbon dioxide during electrolysis. The average current density at the membrane is at least 20 mA/cm2, measured as the area of the cathode gas diffusion layer that is covered by catalyst, and formate ion selectivity is at least 50% at a cell potential difference of 3.0 V.

Abstract: An electrochemical device converts carbon dioxide to a formic acid reaction product. The device includes an anode and a cathode, each comprising a quantity of catalyst. The anode and cathode each have reactant introduced thereto. Two membranes, a cation exchange polymer electrolyte membrane and an anion exchange polymer electrolyte membrane, are interposed between the anode and the cathode, forming a central flow compartment where a carbon dioxide reduction product, such as formic acid, can be recovered. At least a portion of the cathode catalyst is directly exposed to gaseous carbon dioxide during electrolysis. The average current density at the membrane is at least 20 mA/cm2, measured as the area of the cathode gas diffusion layer that is covered by catalyst, and formate ion selectivity is at least 50% at a cell potential difference of 3.0 V.

Abstract: This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by heptatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.

Abstract: An electrochemical device converts carbon dioxide to a formic acid reaction product. The device includes an anode and a cathode, each comprising a quantity of catalyst. The anode and cathode each have reactant introduced thereto. Two membranes, a cation exchange polymer electrolyte membrane and an anion exchange polymer electrolyte membrane, are interposed between the anode and the cathode, forming a central flow compartment where a carbon dioxide reduction product, such as formic acid, can be recovered. At least a portion of the cathode catalyst is directly exposed to gaseous carbon dioxide during electrolysis. The average current density at the membrane is at least 20 mA/cm2, measured as the area of the cathode gas diffusion layer that is covered by catalyst, and formate ion selectivity is at least 50% at a cell potential difference of 3.0 V.

Abstract: This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.

Abstract: This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by heptatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.

Abstract: This invention relates to a use of G-CSF dimer in the treatment of neutropenia. In particular, the recombinant human G-CSF of the present invention can enhance the differentiation and development of neutrophils in animal, and thus effectively reduce the severity of the severe neutropenia and shorten the time of severe neutropenia for the post-chemotherapy cancer patients. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased, providing a better effect in the treatment of neutropenia.

Abstract: This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.

Abstract: This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.

Abstract: This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.

Abstract: This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.

Abstract: This invention relates to a use of G-CSF dimer in the treatment of neutropenia. In particular, the recombinant human G-CSF of the present invention can enhance the differentiation and development of neutrophils in animal, and thus effectively reduce the severity of the severe neutropenia and shorten the time of severe neutropenia for the post-chemotherapy cancer patients. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased, providing a better effect in the treatment of neutropenia.

Abstract: This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.